Hepatitis C: all 2,356 studies
Page 13 of 24. Open to participants first (101), then studies with results posted, then the rest; newest registration first within each.
- Impact of Hepatitis C Therapy and Bone HealthTerminatedNCT03221582Phase 4
- Study of AT-527 in Healthy and HCV-Infected SubjectsCompletedNCT03219957Phase 1
- Impact of Insulin Resistance on Therapeutic Response for Oral Treatment of Chronic Hepatitis C Virus InfectionStatus unknownNCT03212833
- Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in AdultsWithdrawnNCT03208322
- A Retrospective, Observational Study on the Effectiveness of Daclatasvir-Containing Regimens in Patients in KSA, UAE and QatarCompletedNCT03205618
- A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New DrugsCompletedNCT03201718
- Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 PatientsCompletedNCT03200184Phase 4
- Effect of DAAs on Behavior of HCC in HCV PatientsCompletedNCT03200171
- Direct-acting Antivirals and Hepatocellular Carcinoma RecurrenceCompletedNCT03197155
- Identification to Elimination in HCV-Infected IndividualsCompletedNCT03195205Early Phase 1
- The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAsCompletedNCT03188276Early Phase 1
- 8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild FibrosisCompletedNCT03186365Phase 3
- A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV InfectionCompletedNCT03186313Phase 3
- T Regulatory Cells in Hepatitis c Infected PatientsCompletedNCT03186235
- Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in AdultsCompletedNCT03181074
- Pattern of Skin Manifestations in Chronic Hepatitis c Virus Patients Before and After Direct Acting Anti Viral DrugsStatus unknownNCT03170076
- The Effect of Direct Antiviral Therapy on Hepatitis c Virus-related ThrombocytopeniaStatus unknownNCT03169348Not applicable
- the Possible Effect of the Antiviral Inhibitors for Treatment of Hepatitis C Virus Infection in Cardiac FunctionStatus unknownNCT03166943Not applicable
- Hepatitis c and Vitamin D and Iron StatusStatus unknownNCT03166280
- Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for NonadherenceStatus unknownNCT03164902Not applicable
- Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus PatientsStatus unknownNCT03163849Phase 3
- Hepatitis C Treatment Study in MyanmarWithdrawnNCT03158857
- Role of the Host Immunity in the Non-response to Direct Anti-viral Agent (DAA) TherapyCompletedNCT03155113Not applicable
- Hepatitis C Virus Infection in Patients With HemoglobinopathiesCompletedNCT03149289
- Direct Acting Agents in Hepatitis C PatientsCompletedNCT03145844
- Retrospective Efficacy and Safety Study With Elbasvir/Grazoprevir in HCV-infected Patients With Chronic Kidney DiseaseCompletedNCT03145623
- Real World Experience of Chronic Hepatitis C (CHC) Treatment in IsraelCompletedNCT03144440
- Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)WithdrawnNCT03143998Phase 4
- Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAsCompletedNCT03133065Phase 4
- Clinical Performance Evaluation of DxN HCV AssayTerminatedNCT03125408
- Expanded Access to Glecaprevir/ PibrentasvirApproved for marketingNCT03123965
- Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 WeeksCompletedNCT03122132
- Lung Transplant HCV, Pilot StudyActive, not recruitingNCT03112044Early Phase 1
- Effectiveness, Safety and Clinical Outcomes of Elbasvir/Grazoprevir: Results From a Spanish Real World CohortCompletedNCT03111966
- Hepatitis C Virus Detection in Oral Squamous Cell CarcinomaCompletedNCT03109457
- A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5AWithdrawnNCT03105349Phase 4
- A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) InfectionTerminatedNCT03099135Phase 3
- Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infectionCompletedNCT03098121Phase 4
- Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney TransplantWithdrawnNCT03093740Phase 4
- Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C TreatmentCompletedNCT03090035Phase 3
- Pilot Study of HIV and Hepatitis B and C Screening in SurgeryCompletedNCT03088995
- Transplanting Hepatitis C Positive OrgansStatus unknownNCT03086044Phase 4
- Treatment of Egyptian Hepatitis C Genotype 4 Infected Children (and Adolescents) With Combined Sofosbuvir & DaclatasvirCompletedNCT03080415Phase 3
- Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio TherapyCompletedNCT03071133
- Efficacy and Safety of Qurevo Plus Ribavirin Based Therapy for Hepatitis C With or Without Cirrhosis in Haemodialysis PatientsStatus unknownNCT03067883Phase 2
- Treating Hepatitis C in CRF Using Sofosbuvir and DaclatasvirCompletedNCT03063879Phase 4
- Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAsCompletedNCT03063723
- Treatment of Hepatitis C Virus Infection With Generic Sofosbuvir/Ledipasvir in Iranian PatientsStatus unknownNCT03061032Phase 3
- Pilot Feasibility Study of a Cognitive Behavioral Coping Skills (CBCS) Group Intervention for Hep C Therapy PatientsCompletedNCT03057236Not applicable
- Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1BCompletedNCT03050905Phase 4
- Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based TreatmentStatus unknownNCT03042520
- Vertical Transmission of Hepatitis C in Adult Children of Female Baby BoomersCompletedNCT03038763
- Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label TrialCompletedNCT03032666Phase 4
- Orange Juice Consumption in Patients With Hepatitis CCompletedNCT03026569Not applicable
- Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac TransplantWithdrawnNCT03026023Phase 4
- Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis CStatus unknownNCT03022006Phase 4
- Curing HCV in Incarcerated PatientsStatus unknownNCT03018353Phase 4
- Current Treatment of HCV Infection After HSCTCompletedNCT03014986
- Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAVCompletedNCT03004625Phase 3
- MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSVTerminatedNCT03003338Phase 4
- Anticipated and Perceived Benefits Following Hepatitis C TreatmentCompletedNCT03000023
- The HOPE Study: Characterizing Patients With Hepatitis B and CActive, not recruitingNCT02995252
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C InfectionCompletedNCT02992457Phase 4
- PoC-HCV Genedrive Viral Detection Assay Validation StudyCompletedNCT02992184
- Hepatitis C Infection in World Trade Center RespondersCompletedNCT02982993
- Metformin Therapy in HCV InfectionCompletedNCT02972723Phase 4
- Interferon-free Antiviral Treatment of Chronic Hepatitis C Virus Infection Among Opioid-substituted PatientsCompletedNCT02969668
- Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing WorldCompletedNCT02964091Phase 4
- Strategic Transformation of the Market of HCV TreatmentsStatus unknownNCT02961426Phase 2/3
- Strategic Screening for Infectious Diseases (Tuberculosis, HIV, HBV, HCV) Amongst Migrants in FranceStatus unknownNCT02959684
- Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in KoreaCompletedNCT02951364
- Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2CompletedNCT02945228
- Depression, Genes, Cytokines, Chronic Fatigue, Physical Illnesses and Quality of LifeCompletedNCT02943330
- Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver TransplantationSuspendedNCT02935478Not applicable
- Triple Combination DAAs for Treating HCV GT1b SubjectsWithdrawnNCT02932293Phase 2
- Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in KoreaCompletedNCT02907996
- Immune Monitoring of Hepatitis C Under DAA TherapyStatus unknownNCT02904603
- The Prevalence and Severity of HCV Infection in Thalassemia Major and Thalassemia Intermedia in Siriraj HospitalCompletedNCT02904252
- Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected PatientsStatus unknownNCT02897596Phase 3
- The Dublin Zepatier StudyTerminatedNCT02895958Phase 4
- HCV Care Pathway in Ile-de-FranceStatus unknownNCT02893046
- Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.WithdrawnNCT02890719Phase 3
- Ribavirin Bioavailability After Telaprevir ExposureCompletedNCT02881034
- Anti-E1E2 Antibodies (D32.10 Epitope-binding Antibodies) and HCV Triple TherapyCompletedNCT02877199
- Integrating HCV and HIV Screening During the Era of HIV Antigen TestingCompletedNCT02869776Not applicable
- Regression of Liver Fibrosis After Daclatasvir and Asunaprevir TreatmentStatus unknownNCT02865369
- A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal ImpairmentCompletedNCT02864199Phase 4
- Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia VasculitisStatus unknownNCT02856243
- APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and RibavirinCompletedNCT02850289
- Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV InfectionCompletedNCT02836925Phase 2
- Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) ScreeningCompletedNCT02833298Not applicable
- A Follow-up Evaluation Study of PRI-724-1101CompletedNCT02828254
- Investigative Mathematical Modeling of Hospital Transmission of Hepatitis CStatus unknownNCT02826447
- Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)WithdrawnNCT02806362Phase 3
- Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin With or Without InterferonCompletedNCT02804386Phase 4
- Endothelial Dysfunction and Subclinical Atheromatosis in Chronic HCV Infection. Response to DAA Agents.Status unknownNCT02802280Phase 4
- HCV Virions Bound ProteinsCompletedNCT02795403Not applicable
- Association of Vitamin D Binding Protein Polymorphisms With Response to HCV TherapyCompletedNCT02788682
- Eliminating Hepatitis C Transmission by Enhancing Care and Treatment Among HIV Co-infected IndividualsCompletedNCT02786758
- Hepatocellular Carcinoma in HIV-infected PatientsCompletedNCT02785835